Colliers Quick Hits | April 25, 2022
Investors poured record venture capital (VC) funding into the life science industry in 2021, shattering growth records. IPO numbers were off the charts, NIH grants increased, and unprecedented demand was the new paradigm for life science properties. From research and development lab product to cGMP manufacturing spaces, tenant and investor demand has soared, mostly in the nation’s largest and most well-established life science hubs. Boston and the San Francisco Bay Area led the country in absorption, inventory, and VC funding, of which nearly 60% made its way to those two markets, per PitchBook. But other markets are aiming to make their mark as well.
